BIOIO’s CEO is no longer in a lab at Washington University, St. Louis — and in the last couple months the startup set up shop in the Cortex Innovation Community of St. Louis at 4340 Duncan Ave.
Tim Peterson, BIOIO CEO
“I’m no longer with the university,” Tim Peterson told bizblip. He had nothing else to report at this time.
BIOIO uses mechanism of action (MoA) technologies to develop gerotherapies, or drugs that address underlying core aging mechanisms. MOAT combines both experimental and computational approaches to create an accurate understanding of a small molecule‘s MoA, enabling it to be used successfully in multiple clinical indications. This gerotherapy–first approach ensures a pipeline in a pill and helps to ensure drug efficacy.
Bizblip (then 4thEst8) readers first heard of BIOIO (then Bio-I/O) in 2020 when Peterson landed its second SBIR grant. Today the startup has three under its belt, totaling $1,960,850 from the National Institutes of Health, Department of Health and Human Services for both drug target identification and also developing a treatment for insulin resistance.
Links:
